LA JOLLA, Calif., Feb. 2 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (http://www.transdelpharma.com), a specialty pharmaceutical company focused on developing and commercializing non-invasive, topically administered medications, has retained FLP Pharma, a Georgia-based pharmaceutical consultancy, to lead its business development activities, especially the out-licensing of its lead product Ketotransdel(R). FLP Pharma has an experienced track record in negotiating and closing global and regional joint development, licensing, distribution, sales and marketing partnerships and supply agreements with multiple pharmaceutical companies.
“Our Phase 3 clinical trial of Ketotransdel(R) continues to advance,” stated Dr. Juliet Singh, President and CEO of Transdel Pharmaceuticals. “We also continue to explore co-development opportunities in other therapeutic areas utilizing our Transdel(TM) platform technology. With the addition of FLP Pharma and its successful track record, we expect to significantly advance our partnering efforts especially for our lead pain product Ketotransdel(R) and achieve a significant milestone in our growth as a specialty pharmaceutical company.”
“Transdel has implemented a focused approach in negotiating with pharmaceutical companies with a strategic interest in pain management and the requisite infrastructure to successfully commercialize Ketotransdel(R),” stated Terry Nida, Principal of FLP Pharma. “We are open to partnering with pharmaceutical companies with either a global or regional capacity to help us achieve our corporate goals.”
The Company is also investigating other novel and generic drugs and promising therapeutic areas in combination with using their patented transdermal delivery system. Furthermore, the Company recently announced that they are expanding their product development programs to include cosmetic/cosmeceutical products and have initiated discussions with potential sales and marketing partners for specific products.
About Transdel Pharmaceuticals, Inc.
Transdel Pharmaceuticals, Inc. is a specialty pharmaceutical company developing non-invasive, topically-delivered medications. The Company’s innovative patented proprietary Transdel(TM) cream formulation technology is designed to facilitate the effective penetration of drugs through the tough skin barrier to reach the target underlying tissues. In the case of Ketotransdel(R), the Transdel(TM) cream allows the active ingredient ketoprofen, a non-steroidal anti-inflammatory drug, to reach the target soft tissue and exert its well-known anti-inflammatory and analgesic effects. The Company is also investigating other drug candidates and treatments for transdermal delivery using the Transdel(TM) platform technology for products in pain management and other therapeutic areas and for cosmetic/cosmeceutical products. For more information, please visit http://www.transdelpharma.com.
About FLP Pharma LLC
A Pharmaceutical Consulting Service with more than thirty years of international management experience in specialty pharmaceutical, biotech and fully integrated companies; with extensive experience in negotiating licensing agreements for global and regional territories. For more information, please visit www.FLPPharma.com.
Safe Harbor Statement
Statements made in this release that are not historical in nature constitute forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “expects,” “plans,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, and technological changes. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-KSB filed with the SEC on March 26, 2008. Such documents may be read free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements included in this release are made as of the date of this press release, and the Company assumes no obligation to update any such forward-looking statements.
CONTACT: John Lomoro, CFO of Transdel Pharmaceuticals, Inc.,
+1-858-457-5300, johnl@transdelpharma.com; or Investor Relations, Rachel
Colgate or Michael Crawford +1-212-825-3210, or Media Relations, Laura
Colontrelle or Janet Vasquez, +1-212-825-3210, all of The Investor
Relations Group for Transdel Pharmaceuticals, Inc.
Web site: http://www.transdelpharma.com/
